Verzenio/Verzenios (abemaciclib) vs Nerlynx (neratinib)

Verzenio (abemaciclib) and Nerlynx (neratinib) are both oral medications used in the treatment of certain types of breast cancer, but they target different proteins involved in cancer cell growth. Verzenio is a CDK4/6 inhibitor that is typically prescribed for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer, often in combination with an aromatase inhibitor or fulvestrant. In contrast, Nerlynx is a pan-HER inhibitor used primarily as extended adjuvant therapy for early-stage HER2-positive breast cancer to reduce the risk of cancer recurrence after initial treatment with trastuzumab. The choice between Verzenio and Nerlynx would depend on the specific characteristics of the breast cancer, such as hormone receptor and HER2 status, as well as the patient's previous treatments and overall health profile. A healthcare provider would consider these factors, along with potential side effects and drug interactions, to determine the most appropriate treatment option.

Difference between Verzenio/Verzenios and Nerlynx

Metric	Verzenio/Verzenios (abemaciclib)	Nerlynx (neratinib)
Generic name	Abemaciclib	Neratinib
Indications	HR-positive, HER2-negative advanced or metastatic breast cancer	Extended adjuvant treatment of HER2-positive early-stage breast cancer
Mechanism of action	CDK4 & CDK6 inhibitor	Tyrosine kinase inhibitor
Brand names	Verzenio, Verzenios	Nerlynx
Administrative route	Oral	Oral
Side effects	Diarrhea, neutropenia, nausea, abdominal pain, infections	Diarrhea, nausea, abdominal pain, fatigue, rash
Contraindications	None specifically listed; use caution in liver impairment, thrombosis, and pregnancy	Liver disease, severe kidney impairment, and concurrent use of strong CYP3A4 inhibitors
Drug class	Antineoplastic agent, kinase inhibitor	Antineoplastic agent, kinase inhibitor
Manufacturer	Eli Lilly and Company	Puma Biotechnology, Inc.

Efficacy

Verzenio (Abemaciclib) Efficacy in Breast Cancer

Verzenio, also known as abemaciclib, is a targeted therapy approved for the treatment of certain types of breast cancer. Specifically, it is indicated for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Abemaciclib is a CDK4/6 inhibitor that works by interfering with the proliferation of cancer cells. Clinical trials have demonstrated that Verzenio, especially when combined with an aromatase inhibitor or fulvestrant, can significantly extend progression-free survival in women with this subtype of breast cancer. It has also been shown to be beneficial as a monotherapy in patients who have previously received hormone therapy and chemotherapy.

In the pivotal MONARCH 2 and MONARCH 3 trials, abemaciclib in combination with endocrine therapy showed a substantial improvement in progression-free survival compared to endocrine therapy alone. The MONARCH 1 trial, which evaluated abemaciclib as a single agent, also reported a meaningful clinical benefit in terms of objective response rate and duration of response in patients with refractory metastatic breast cancer. These results have established Verzenio as a valuable addition to the treatment options for HR+, HER2- advanced breast cancer.

Nerlynx (Neratinib) Efficacy in Breast Cancer

Nerlynx, known generically as neratinib, is an oral tyrosine kinase inhibitor specifically approved for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Neratinib targets the HER2 protein and is designed to block the proliferation of cancer cells that overexpress this receptor. The approval of Nerlynx was largely based on the results of the ExteNET trial, which showed a statistically significant improvement in invasive disease-free survival when compared to placebo after two years of follow-up in patients who had completed one year of trastuzumab therapy.

While the benefits of Nerlynx in extending disease-free survival are clear, it is important to note that the medication is associated with a high incidence of diarrhea, which can be a significant side effect requiring proactive management. Despite this, Nerlynx remains an important therapeutic option for reducing the risk of recurrence in patients with early-stage HER2-positive breast cancer following initial treatment. Ongoing studies continue to evaluate the long-term benefits and optimal use of Nerlynx in the adjuvant setting.

Regulatory Agency Approvals

Verzenio/Verzenios

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia

Nerlynx

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia

Access Verzenio/Verzenios or Nerlynx today

If Verzenio/Verzenios or Nerlynx are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Verzenio/Verzenios

Buy Nerlynx

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: